Huluwa Pharmaceutical Group ascends to the 40th place in the List of Top 100 Traditional Chinese Medicine Enterprises by continually improving its strength!

The much-anticipated 2023 China Medical and Health Industry Symbiosis Conference (MHIS), was held in Huzhou, Zhejiang Province, from June 25 to 28, 2023. More than 5,000 representative industrial experts, association leaders, and pharmaceutical entrepreneurs attended the conference to discuss on the future development of the medical and health industry. In the conference, Huluwa Pharmaceutical Group is once again included in the List of Top 100 Traditional Chinese Medicine Enterprises released by MENET.

Huluwa Pharmaceutical keeps ascending in the List of Top 100 Traditional Chinese Medicine Enterprises in recent years

The 2023 Top 100 Chinese Pharmaceutical Companies List Series are widely recognized by the pharmaceutical industry in China since companies on the list excel in business innovation and promotion performance.

Huluwa Pharmaceutical Group is ranked 40th in the List of 2023 Top 100 Traditional Chinese Medicine Enterprises for its outstanding performance in innovation, product quality and market influence and has climbed up 3 places compared with its position in the previous year.

Huluwa Pharmaceutical remains an active player in the green development of the pharmaceutical industry in recent years, focusing on drugs for pediatric use and on continual innovative improvement of classic TCM preparations. In the process, it has acquired its core competitiveness and creativity by accelerating its full-coverage industrial chain deployment in innovative pediatric drugs, health supplements, special medicine foods, and medical devices. The group’s overall strength in business development has been continually improving as a result of its all-round investment in innovative R&D, intelligent manufacturing, and digital technology-based operation.

Growth-focusing Summit

At the conference, Liu Jingping, Secretary of the Party Committee and Chairman of Huluwa Pharmaceutical Group was invited to preside over the MHIS Top Insight Summit in which a number of representative experts, scholars, and entrepreneurs in the industry engaged in in-depth discussions of the new ordeals and new challenges confronting the pharmaceutical industry in the current economic environment. Participants in the summit brainstormed about how to blaze new approaches and identify new opportunities in line with the “opening up new landscape in resilient progress”.

Chairman Liu Jingping discussed on such topics as “how to achieve stable growth in the medicine retail industry” with the big shots in the pharmaceutical industry and chain drug stores at the MHIS Dialog seminar. She expressed that big healthcare is becoming a new point of growth in pharmaceutical industry in the wake of the increasing health awareness of the public and the government’s increasing policy support to the pharmaceutical industry and the big healthcare industry. Presently, Huluwa Pharmaceutical is aggressively expanding its product pipelines and product groups by increasing its investment in R&D, optimizing product portfolio structure, expanding products’ application area, and adding new health supplement, medical device, and special medicine food products. Moreover, the company keeps improving its resilience in development through continuous investment in professional service capability, branding, and business on cross-border e-commerce platform.

Huluwa Pharmaceutical has been adhering to the mission of “Healthy Chinese Children” and the value of technological innovation and collaboration-based development since its foundation. In the future, it will continue to pursue robust and high-standard growth by expanding and optimizing its product portfolio and marketing resource arrangement with global vision and by continual improvement of its core competitiveness and brand value, so as to make greater contribution to a healthy China.